GLP-1 receptor agonists mimic hormones to curb appetite, slow digestion, and promote 15-20% sustained weight loss when paired with diet/exercise

BMI ≥30, or ≥27 with comorbidities (e.g., diabetes, hypertension); prior lifestyle attempts required—varies by country (UK NHS tiers, Germany private).​

Nausea, GI upset (mild, temporary); rare thyroid/vision risks monitor with doctor oversight.

AOD targets fat breakdown (2-3kg short-term), semaglutide excels in appetite control and overall loss.​

Prescription-only via GP/specialist; private €200-350/month, limited public coverage.​